Please join us for our next ODS Educational Series Webinar: RYBREVANT® (amivantamab-vmjw) + LAZCLUZE® (lazertinib) Proactive Strategies to Help Patients on Therapy. Take part in a deep dive into prophylactic approaches associated with RYBREVANT® + LAZCLUZE® treatment and gain insights about efficacy and safety. Please read full Prescribing Information for RYBREVANT® (https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/RYBREVANT-pi.pdf) and full Prescribing Information for LAZCLUZE® (https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/LAZCLUZE-pi.pdf).

Moderator: Mario E. Lacouture, MD, FAAD Founding President, Oncodermatology Society Chief, Dermatology Division, Department of Medicine NYU Grossman Long Island School of Medicine Medical Director, Symptom Management Program Perlmutter Cancer Center NYU Langone Hospital – Long Island

CLICK HERE TO REGISTER